Concluding remarks The transcription factor NRF2 is central to the regulatory network governing cellular defenses against toxic and oxidative insults
If you're on a GLP-1 receptor agonist - semaglutide, tirzepatide, or another GLP-1-class medication - and you're experiencing meaningful weight loss, here's what the published evidence and clinical consensus suggest a responsible musculoskeletal protection plan looks like
You are encouraged to ask these questions
A key trial found that 600mg per day provided the best balance of effectiveness and tolerability, reducing instances of nausea, dizziness, and GI discomfort.4 A separate review of multiple studies supports this, concluding that 600mg daily is effective and well-tolerated for conditions like diabetic neuropathy, insulin resistance, and oxidative stress.5 That body of research has established 600mg of racemic ALA as a standard dose in clinical studies, thanks to its consistent balance of efficacy and tolerability
And this week they published a report outlining their findings: Title: Diabetes medications and risk of Parkinsons disease: a cohort study of patients with diabetes Authors: Brauer R, Wei L, Ma T, Athauda D, Girges C, Vijiaratnam N, Auld G, Whittlesea C, Wong I, Foltynie T
Vagal nerve stimulation and reflux